Atrial Fibrillation, Cardiac Remodeling, Atrial, Sacubitril/Valsartan
Conditions
Keywords
Atrial Fibrillation, Cardiac Remodeling, Sacubitril/Valsartan
Brief summary
The purpose of this clinical randomized trial is to evaluate the efficacy and safety of Sacubitril/Valsartan compared with ARB in improving cardiac remodeling in patients With Enlarged Left Atrium Diameter and Persistent AF.
Detailed description
Atrial fibrillation is one of the most common arrhythmia around the word. Prolonged atrial fibrillation may lead to structural changes in the heart such as atrial enlargement, which is an important risk factor for heart failure. Sacubitril/Valsartan is a new drug for the treatment of heart failure, previous studies have shown that it has a good effect in improving cardiac function. For patients with persistent atrial fibrillation and enlarged left atrial, the effect of reversing cardiac remodeling after catheter ablation is unclear. Some studies have described its positive effects in improving cardiac remodeling, but there is still no large-scale randomized controlled trial to further confirm. The investigators hypothesized that Sacubitril/Valsartan can reverse cardiac remodeling in patients with persistent atrial fibrillation and enlarged left atrium compared with ARB after catheter ablation.
Interventions
DRUGSacubitril-Valsartan
After catheter ablation,during a single blind, run-in period, participants received placebo. Then started with 50 mg LCZ696 for 2-4 weeks, then uptitrated to 100 mg bid for 2-4 weeks, and thereafter, uptitrated to 200 mg bid or tolerable maximum dose ≥6 months.
DRUGValsartan
After catheter ablation,during a single blind, run-in period, participants received placebo. Then started with 40 mg Valsartan daily (qd) for 2-4 weeks, then were uptitrated to 80mg qd or tolerable maximum dose ≥6 months.
Sponsors
The Second Affiliated Hospital of Chongqing Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
two groups,group one is for Sacubitril/valsartan 200mg bid or tolerable maximum dose, group two is for valsartan 80mg qd or tolerable maximum dose.
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with persistent atrial fibrillation undergoing catheter ablation within 2 weeks. 2. ≥18 and ≤75 years of age. 3. Left atrium diameter（LAD）≥35mm, With or without right atrium diameter（RAD）≥40mm，diagnosed by Echocardiographic. 4. patient who are mentally and linguistically able to understand the aim of the trial and to show sufficient compliance in following the trial protocol. 5. Patients receiving ACE inhibitors (ACEI), angiotensin receptor blockers (ARB) and/or a beta blockers must be on a stable dose of these medications stable for the 1 month period prior to Visit. 6. Patients with a controlled systolic BP, defined as a target systolic BP less than 140 mm Hg; participants with BP up to and including 160 mmHg are eligible for enrollment if they are on three or more medications to control BP at randomization. 7. Patients must have an eGFR ≥ 30 ml/min/1.73 m2 at Visit 1 (calculated by the Modification of Diet in Renal Disease formula). 8. Patients with a potassium ≤5.2 mmol/l at Visit 1.
Exclusion criteria
1. Patients with prosthetic valves. 2. Any previous LA suigery. 3. Acute coronary syndrome (including MI), cardiac surgery, other major CV surgery within 3 months , or urgent percutaneous coronary intervention within 3 months or and elective PCI within 30 days prior to entry. 4. Presence of hemodynamically significant mitral and /or aortic valve disease. 5. Presence of hemodynamically significant obstructive lesions of left ventricular outflow tract, including aortic stenosis. 6. Current acute decompensated HF requiring therapy. 7. Allergic to drugs or active ingredients (shakuba, valsartan) or any excipients。 8. Patients with previous history of angioedema associated with ACEI or ARB treatment. 9. Patient with hereditary or idiopathic angioedema. 10. patient with severe liver damage, biliary cirrhosis and cholestasis. 11. Patient with Renal artery stenosis.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Left atrial size changes compared to baseline levels | 6months and 12 months | Echocardiography was used to assess the size of the left atrium, and the changes in atrial structure and baseline levels were compared. The effective index was a gradual decrease in the atrium. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| all-cause death | 12 months | all-cause death |
| Time to first documented recurrence of atrial arrhythmias | 12 months | Time to first documented recurrence of atrial arrhythmias |
| Number of hospitalizations caused by heart failure | 12 months | Number of hospitalizations caused by heart failure |
| Freedom from AF or AT without the use of antiarrhythmic drugs at 12 months after a single ablation procedure. | 12 months | Confirmation of atrial fibrillation by electrocardiogram or dynamic electrocardiogram during follow-up. Patients with AF or AT that occurred in the first 3 months after the ablation (blanking period) were censored. Each episode that lasted \>30 s was regarded as a recurrence. |
| Number of patients requires adjustment of the drug because of Hypotension | 12 months | Number of patients requires adjustment of the drug because of Hypotension |
| Change From Baseline in Echocardiography Parameters: Left Ventricular Ejection Fraction | 12 months | A limited two-dimensional and Doppler ECHO examination was done to assess ECHO parameters. |
| Right atrial size changes compared to baseline levels | 12 months | Echocardiography was used to assess the size of the right atrium, and the changes in atrial structure and baseline levels were compared. The effective index was a gradual decrease in the atrium. |
| All-cause hospitalizations | 12 months | All-cause hospitalizations |
Contacts
Primary ContactZHIYU LING, MD
Backup ContactYANPING XU
Outcome results
None listed